2022 Guide to Patient Support Services

Teva Oncology

Teva Oncology Support Services

Teva CORE
888-587-3263
Teva Cares
877-237-4881

Teva Oncology offers the Comprehensive Oncology Reimbursement Expertise (CORE) program and the Teva Cares Foundation Patient Assistance Program to help patients while taking a Teva Oncology treatment (Table).

Teva CORE

The Teva CORE program helps eligible patients, their caregivers, and healthcare professionals navigate the reimbursement process through a range of services, including benefit verification, coverage determination, prior authorizations, letters of medical necessity, and referrals to the Teva Cares Foundation.

For patients prescribed Granix, Herzuma, and Truxima, Teva CORE offers a Patient Savings Program. Patients may be eligible for this if they:

  • Are at least 18 years of age
  • Have commercial insurance
  • Do not participate in Medicare, Medicaid, or other government insurance program.

Click here to enroll your patient in the Teva CORE program.

Teva Cares Foundation Patient Assistance Program

If your patient is uninsured or underinsured, they may be eligible to receive their prescribed Teva medication at no cost. Patients must meet certain financial and insurance coverage criteria to be eligible. Patient Assistance Program applications are available online.

TABLE Teva Oncology/Supportive Care Drugs

Drugs
Indications
Patient support programs

Drug
Bendeka (bendamustine hydrochloride)
Indications
Treatment of CLL; treatment of indolent B-cell NHL progressing during/within 6 months of rituximab or a rituximab-containing regimen
Patient support programs

Drug
Granix (tbo-filgrastim)
Indications
To reduce severe neutropenia in patients aged ≥1 months with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with febrile neutropenia
Patient support programs

Drug
Herzuma (trastuzumab-pkrb)
Indications
Patient support programs

Drug
Synribo (omacetaxine mepesuccinate)
Indications
Treatment of adults with chronic- or accelerated-phase chronic myeloid leukemia and resistance or intolerance to ≥2 tyrosine kinase inhibitors
Patient support programs

Drug
Treanda (bendamustine hydrochloride)
Indications
Treatment of CLL; treatment of indolent B-cell NHL that progressed during/within 6 months of rituximab or a rituximab-containing regimen
Patient support programs

Drug
Trisenox (arsenic trioxide)
Indications
First-line treatment of adults with low-risk APL characterized by t(15;17) translocation or PML/RAR-alpha gene expression, in combination with tretinoin; treatment of APL characterized by t(15;17) translocation or PML/RAR-alpha gene expression, and is refractory to, or relapsed after, retinoid and anthracycline chemotherapy
Patient support programs

Drug
Truxima (rituximab-abbs)
Indications
Patient support programs

APL indicates acute promyelocytic leukemia; CLL, chronic lymphocytic leukemia; NHL, non-Hodgkin lymphoma.

Herzuma (trastuzumab-pkrb) Indications

Treatment of HER2-overexpressing node-positive or -negative breast cancer, in combination with doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel, or in combination with docetaxel and carboplatin; as monotherapy after anthracycline-based therapy; first-line treatment of HER2-overexpressing metastatic breast cancer, in combination with paclitaxel, or as monotherapy in patients who received ≥1 chemotherapy regimens for metastatic disease; treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma, in combination with cisplatin and capecitabine or 5-fluorouracil, in patients who have not received previous therapy for metastatic disease

Truxima (rituximab-abbs) Indications

Treatment of adults with relapsed or refractory, low-grade or follicular, CD20-positive B-cell NHL as a single agent; treatment of previously untreated follicular, CD20-positive, B-cell NHL in combination with first-line chemotherapy and, in patients achieving a complete or partial response to a rituximab product in combination with chemotherapy, as single-agent maintenance therapy; treatment of non-progressing (including stable disease), low-grade, CD20-positive, B-cell NHL as a single agent after first-line cyclophosphamide, vincristine, and prednisone (CVP) chemotherapy; treatment of previously untreated diffuse large B-cell, CD20-positive NHL in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) or other anthracycline-based chemotherapy regimens; treatment of previously untreated and previously treated CD20-positive CLL in combination with fludarabine and cyclophosphamide

Report Broken Links

Have you encountered a problem with a URL (link) on this page not loading correctly or is displaying an error message?

Help us fix it! Report broken links here.

Report Broken Links

Report Broken Links

*OPM Webpage
Please copy the URL (link) of the OPM webpage you are currently on.
*Broken Link
Please copy the URL (link) to the external webpage that is not displaying content correctly.
Errors include, but are not limited to:
  • "This site can’t be reached"
  • "Hmm. We’re having trouble finding that site."
  • "Hmmm… can't reach this page"
  • "404 Error: Page not found"
Comments
(Optional)